Opportunistic infections and biologic therapies in immune-mediated inflammatory diseases: consensus recommendations for infection reporting during clinical trials and postmarketing surveillance.

Academic Article

Abstract

  • No consensus has previously been formed regarding the types and presentations of infectious pathogens to be considered as 'opportunistic infections' (OIs) within the setting of biologic therapy. We systematically reviewed published literature reporting OIs in the setting of biologic therapy for inflammatory diseases. The review sought to describe the OI definitions used within these studies and the types of OIs reported. These findings informed a consensus committee (infectious diseases and rheumatology specialists) in deliberations regarding the development of a candidate list of infections that should be considered as OIs in the setting of biologic therapy. We reviewed 368 clinical trials (randomised controlled/long-term extension), 195 observational studies and numerous case reports/series. Only 11 observational studies defined OIs within their methods; no consistent OI definition was identified across studies. Across all study formats, the most numerous OIs reported were granulomatous infections. The consensus group developed a working definition for OIs as 'indicator' infections, defined as specific pathogens or presentations of pathogens that 'indicate' the likelihood of an alteration in host immunity in the setting of biologic therapy. Using this framework, consensus was reached upon a list of OIs and case-definitions for their reporting during clinical trials and other studies. Prior studies of OIs in the setting of biologic therapy have used inconsistent definitions. The consensus committee reached agreement upon an OI definition, developed case definitions for reporting of each pathogen, and recommended these be used in future studies to facilitate comparison of infection risk between biologic therapies.
  • Published In

    Keywords

  • Anti-TNF, Infections, Rheumatoid Arthritis, Biological Therapy, Clinical Trials as Topic, Consensus, Global Health, Humans, Immunosuppressive Agents, Morbidity, Opportunistic Infections, Product Surveillance, Postmarketing, Risk Factors
  • Digital Object Identifier (doi)

    Author List

  • Winthrop KL; Novosad SA; Baddley JW; Calabrese L; Chiller T; Polgreen P; Bartalesi F; Lipman M; Mariette X; Lortholary O
  • Start Page

  • 2107
  • End Page

  • 2116
  • Volume

  • 74
  • Issue

  • 12